













Experimental Cancer Medicine Centres (ECMC): Accelerating innovation in early-phase oncology research



- A unique network of 18 adult and 11 paediatric research centres integrating NHS and co-located University research capabilities
- Joint investment from CRUK and the UK government: £7m per annum



- World-class clinical, scientific and operational expertise
- Access to a broad patient population for both commercial and investigator-sponsored trials



- A streamlined process to facilitate study placement and industry/academic collaborations
- Engaging key stakeholders to shape the UK research environment




















World-class clinical and scientific ONCOLOGY expertise





Adult ECMC Network

Belfast
Vicky Coyle
Kienan Savage
Birmingham
Gary Middleton
Cambridge
Duncan Jodrell
Cardiff
Robert Jones
Oliver Ottmann
Edinburgh
David Cameron
Stefan Symeonides
Glasgow
Jeff Evans
Richard Wilson

London - Barts
Peter Schmid
Rowan Miller
London - ICR
Johann Sebastian de l
Udai Banerji
London - Imperial
Michael Seckl
Eric Aboagye
London - Kings HPs
James Spicer
Anand Purushotham
London - UCL
Martin Forster
John Hartley
Leicester
Anne Thomas
Karen Brown



Liverpool

Lisa Howell



Paediatric ECMC Network

Birmingham
Bruce Morland
Pamela Kearns
Andrew Peet
Frank Mussai
Bristol
Anthony Ng
Cambridge
Amos Burke
Richard Gilbertson
Sam Behjati

Glasgow
Milind Ronghe
London - ICR
Lynley Marshall
Louis Chesler
Sally George
London - UCL
Darren Hargrave
John Anderson
Karin Straathof
Leeds
Martin Elliot

Manchester
Guy Makin
Newcastle
Quentin Campbell-Hewson
Gareth Veal
Deborah Tweddle
Southampton
Juliet Gray

ECMC Clinical Research Capabilities



Precision medicine

- Comprehensive genomic profiling of solid tumour, blood cancer and ctDNA
- Adopting and developing cutting-edge technologies and bioinformatics
- Biomarker stratified trials



Combination Therapy

- Design and delivery of complex trials including novel therapy, radiotherapy and technology
- Seamless transition of early- to latephase research



Immunotherapy

- First in Human novel agent trials
- CAR-T
- Oncolytic virus
- Tumour-infiltrating lymphocytes



Haematology

- Access to diverse Haematological cancer expertise and patients
- Academic Drug Development Insight



Experimental Cancer Medicine Centre Network

400 Phase I & II trials conducted


Incl. 150 trials started in 2019

50% International trials

3,000 Patients recruited


77% Adult; 23% Paed; Paed/Adult

Study Start Up 80 days





ECMC expression of interest process:



The ECMC Programme Office is your central team, facilitating:

- A single point of entry for streamlined early feasibility, ECMC site engagement and study placement
- Network-wide standard templates incl. NDA, one signature to access 18 adult & 11 paediatric centres
- Enhanced Patient Referral Capabilities Our proprietary tool EC Trial Finder, enables clinicians to search ECMC trials open for recruitment (by molecular stratification)
- Study delivery and patient engagement support via the National Institute for Health Research
- Academic Engagement to support protocol development and experimental research collaborations



Enabling Academic Collaborations

Academic Engagement

Research Proposals & Prioritisation

ECMC hosted Webinar

ECMC Triage process and/or workshop

Network wide NDA

Streamlined EOI and triage process

Industry Partner

Industry Partner shares:
Type of collaboration of interest
Agents available
Existing pre clinical, clinical insights
Funding and/or drug distribution
Timeframe

Industry partner reviews and prioritises ECMC generated early phase research proposals

Sponsorship
Timelines

Support

Governance

ECMC Paediatric Network

5 ITCC designated first-in-child centres

Advanced imaging and biobanking

Whole genome & targeted panel sequencing






- UK-wide prospective molecular profiling programme for children with relapsed cancer
- Biomarker platform for stratified enrolment of patients onto precision medicine trials e.g. ESMART
- Rapid turnaround of 21-28 days

150 relapsed patients profiled

Dedicated patient referral network

- Enhanced recruitment and data collection
- 4 Regional relapse discussion panels







ECMC Network: thinking smarter, delivering sooner

Effective delivery of Complex Innovative Design (CID) cancer trials (a consensus paper co-ordinated by the ECMC network)

- Published in the British Journal of Cancer
- Outlines recommendations for the effective delivery of CID trials in the UK & Europe for the first time
- Podcast series on the delivery & management of CID trials with the HRA and NIHR



Network Intelligence

 A network-wide platform to enable greater insight of network capabilities

Study Start-Up

- Implementing efficiencies to enable faster trial set-up in paediatric trials
- Exploring efficiencies in adult trials



Contact us

Programme Office

W: www.ecmcnetwork.org.uk

E: ECMCadmin@cancer.org.uk

